As such, it may be important to consider targeting TA availability or modulation of TAAR1 expression in an effort to curb Ca2+-associated visceral hypersensitivity in IBS patients with severe abdominal pain. The gene discussed is TAAR1; the disease is irritable bowel syndrome.